These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 25871620

  • 1. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.
    VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P.
    Am J Surg Pathol; 2015 Jul; 39(7):939-47. PubMed ID: 25871620
    [Abstract] [Full Text] [Related]

  • 2. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
    VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P.
    Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
    [Abstract] [Full Text] [Related]

  • 3. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K, Wang Y, Marketkar S, Kalife ET, Steinhoff MM.
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [Abstract] [Full Text] [Related]

  • 4. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
    Nakamura R, Yamamoto N, Shiina N, Miyaki T, Ikebe D, Itami M, Shida T, Miyazaki M.
    Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
    [Abstract] [Full Text] [Related]

  • 5. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
    Xian Z, Quinones AK, Tozbikian G, Zynger DL.
    Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
    [Abstract] [Full Text] [Related]

  • 6. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA, Bauer KR, Brown MM, Caggiano V.
    Breast J; 2009 Apr; 15(6):593-602. PubMed ID: 19764994
    [Abstract] [Full Text] [Related]

  • 7. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J, Piscuoglio S, Aggarwal G, Magda J, Friedlander MA, Murray M, Akram M, Reis-Filho JS, Weigelt B, Edelweiss M.
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [Abstract] [Full Text] [Related]

  • 8. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F, Simionescu C, Georgescu CV, Pirici E.
    Rom J Morphol Embryol; 2011 Feb; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [Abstract] [Full Text] [Related]

  • 9. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
    Halilovic A, Bulte J, Jacobs Y, Braam H, van Cleef P, Schlooz-Vries M, Werner A, Boelens O, Nagtegaal I, de Wilt H, Bult P.
    J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
    [Abstract] [Full Text] [Related]

  • 10. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE, Wu Y, Teot LA, Cai G.
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [Abstract] [Full Text] [Related]

  • 11. False-negative core needle biopsies of the breast: an analysis of clinical, radiologic, and pathologic findings in 27 concecutive cases of missed breast cancer.
    Shah VI, Raju U, Chitale D, Deshpande V, Gregory N, Strand V.
    Cancer; 2003 Apr 15; 97(8):1824-31. PubMed ID: 12673707
    [Abstract] [Full Text] [Related]

  • 12. Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens.
    Hariri N, Hasteh F, Walavalkar V, Roma AA, Fadare O.
    Appl Immunohistochem Mol Morphol; 2019 Jan 15; 27(1):1-7. PubMed ID: 28549033
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
    Yang YF, Liao YY, Li LQ, Xie SR, Xie YF, Peng NF.
    Pathol Res Pract; 2013 Dec 15; 209(12):797-802. PubMed ID: 24183366
    [Abstract] [Full Text] [Related]

  • 18. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
    Kumar SK, Gupta N, Rajwanshi A, Joshi K, Singh G.
    Cytopathology; 2012 Jun 15; 23(3):181-6. PubMed ID: 21375607
    [Abstract] [Full Text] [Related]

  • 19. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
    Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B.
    J BUON; 2015 Jun 15; 20(1):28-34. PubMed ID: 25778292
    [Abstract] [Full Text] [Related]

  • 20. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N, Neskovic-Konstantinovic Z.
    J BUON; 2013 Jun 15; 18(4):851-8. PubMed ID: 24344008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.